Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Dushyant Verma, Hagop Kantarjian, Sara S. Strom, Mary Beth Rios, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds